Introduction
Levocabastine is a novel selective H-receptor antagonist which has been specifically developed as eye drops and nasal spray for the topical treatment of allergic rhinoconjunctivitis. Levocabastine is the most potent antihistamine available to date, being some 15 000 times more potent than chlorpheniramine on a molar basis and expressing antihistaminic activity at doses as low as 0.002 mg/kg. 2 Onset of action is rapid, typically occurring within minutes of instillation, with duration of effect sufficiently long to4Permit a convenient twice daily dosing regimen. '
The efficacy and tolerability of levocabastine eye drops in the treatment of allergic conjunctivitis in adults is well documented. 5 Comparative studies have shown that levocabastine eye drops administered twice daily are at least as effective as standard daily doses of oral antihistamines ('-1 and significantly more effective than sodium cromoglycate four times daily. 11 '12 Levocabastine eye drops have also been shown to be significantly more effective than the topical antihistamine/vasoconstrictor combination, antazoline/naphazoline, for the treatment of ocular symptoms, 1 with a tolerability profile comparable with that of sodium cromoglycate or placebo. 14 Preliminary studies in children, involving a total of 157 patients, have shown that levocabastine eye drops administered twice daily are at least as effective and well-tolerated as sodium cromoglycate four times daily for the treatment of allergic 1, 16 conjunctivitis, both as single agent therapy' and as an adjunct to oral antihistamine therapy. The present study was undertaken to assess the efficacy and tolerability of ocular levocabastine in the routine treatment of seasonal allergic conjunctivitis in a much larger group of children and adolescents. Assessment of any correlation between efficacy, tolerability and age (< 12 years and > 12 years) was a secondary aim. (end-point values) . Similarly, the incidence of patients with moderate to 80"-severe conjunctival erythema, the most severe ._ ocular sign at baseline, was reduced from 89% to 9% in patients < 12 years and from 88% to 8% g 40-in those > 12 years over the 4-week treatment period (end-point values) (p < 0.001).
Materials and Methods
Analysis of the data generated in the patients' 
